Cartesian Therapeutics Inc — Balance Sheet (NASDAQ:RNAC) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Total assets 165.44 M159.88 M165.89 M305.05 M435.02 M Total liabilities 183.44 M137.36 M72.06 M444.68 M441.82 M Total equity 18.01 M22.52 M93.83 M440.18 M6.8 M Total liabilities & shareholders' equities 165.44 M159.88 M165.89 M305.05 M435.02 M Total debt ————— Net debt —————

Haberler

Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?

Johnson & Johnson Touts Positive Results For Lupus Treatment - Johnson & Johnson (NYSE:JNJ)

2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares

H.C. Wainwright, Cartesian Therapeutics hisse senedi fiyat hedefini 40 dolardan 30 dolara düşürdü

H.C. Wainwright lowers Cartesian Therapeutics stock price target to $30 from $40

Cartesian: Maintaining Buy Rating For Expansion Of Descartes-08 For Myositis (NASDAQ:RNAC)

What's Going On With Cartesian Therapeutics Stock Friday? - Cartesian Therapeutics (NASDAQ:RNAC)

BTIG, Cartesian Therapeutics için hedef fiyatı 44 dolara yükseltti

Cartesian Therapeutics stock price target raised to $44 by BTIG

Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday - Applied Mat (NASDAQ:AMAT), Gap (NYSE:GAP)

Kyverna Stock: Immune Reset Is Clinically Validated, Market Ignores Potential

Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates